Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Maurizio Benucci, Arianna Damiani, Mariangela Manfredi, Maria Infantino, Valentina Grossi & Francesca Li Gobbi. (2019) Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life. ClinicoEconomics and Outcomes Research 11, pages 405-409.
Read now
Read now
Jeroen P. Jansen, Devin Incerti, Alex Mutebi, Desi Peneva, Joanna P. MacEwan, Bradley Stolshek, Primal Kaur, Mahdi Gharaibeh & Vibeke Strand. (2017) Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. Journal of Medical Economics 20:7, pages 703-714.
Read now
Read now
Michael L. Ganz, Brian Bekker Hansen, Xavier Valencia & Martin Strandberg-Larsen. (2015) Key data elements for use in cost-utility modeling of biological treatments for rheumatoid arthritis. Journal of Medical Economics 18:5, pages 366-375.
Read now
Read now
Nicole W Tsao, Kam Shojania & Carlo A Marra. (2014) Cost–effectiveness of abatacept for moderate-to-severe rheumatoid arthritis. Expert Review of Pharmacoeconomics & Outcomes Research 14:1, pages 9-18.
Read now
Read now
Articles from other publishers (14)
S Sajith Kumar, Bhavani Shankara Bagepally & Akhil Sasidharan. (2023) Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies. Clinical Drug Investigation 43:2, pages 97-108.
Crossref
Crossref
Matthew Sussman, Jeffrey C. Yu & Joseph Menzin. (2020) Do Research Groups Align on an Intervention’s Value? Concordance of Cost-Effectiveness Findings Between the Institute for Clinical and Economic Review and Other Health System Stakeholders. Applied Health Economics and Health Policy 18:4, pages 477-489.
Crossref
Crossref
Salah Ghabri, Laurent Lam, François Bocquet & Hans-Martin Spath. (2020) Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs. PharmacoEconomics 38:5, pages 459-471.
Crossref
Crossref
Evo Alemao, Maiwenn J. Al, Annelies A. Boonen, Matthew D. Stevenson, Suzanne M. M. Verstappen, Kaleb Michaud, Michael E. Weinblatt & Maureen P. M. H. Rutten-van Mölken. (2018) Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. PLOS ONE 13:10, pages e0205013.
Crossref
Crossref
Fabrizio Cantini, Laura Niccoli, Carlotta Nannini, Emanuele Cassarà, Olga Kaloudi, Ennio Giulio Favalli, Andrea Becciolini, Martina Biggioggero, Maurizio Benucci, Francesca Li Gobbi, Valentina Grossi, Maria Infantino, Francesca Meacci, Mariangela Manfredi, Serena Guiducci, Silvia Bellando-Randone, Marco Matucci-Cerinic, Rosario Foti, Marcella Di Gangi, Marta Mosca, Chiara Tani, Fabrizio Palmieri & Delia Goletti. (2016) Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Seminars in Arthritis and Rheumatism 45:5, pages 519-532.
Crossref
Crossref
Marieke Krol & Werner Brouwer. (2015) Unpaid work in health economic evaluations. Social Science & Medicine 144, pages 127-137.
Crossref
Crossref
Jaana T. Joensuu, Saara Huoponen, Kalle J. Aaltonen, Yrjö T. Konttinen, Dan Nordström & Marja Blom. (2015) The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review. PLOS ONE 10:3, pages e0119683.
Crossref
Crossref
Stefan Scholz & Thomas Mittendorf. (2014) Modeling rheumatoid arthritis using different techniques - a review of model construction and results. Health Economics Review 4:1.
Crossref
Crossref
H. G. M. van Haalen, J. L. Severens, A. Tran-Duy & A. Boonen. (2014) How to Select the Right Cost-Effectiveness Model?. PharmacoEconomics 32:5, pages 429-442.
Crossref
Crossref
Erkki J Soini, Miina Leussu & Taru Hallinen. (2013) Administration costs of intravenous biologic drugs for rheumatoid arthritis. SpringerPlus 2:1.
Crossref
Crossref
Kostas Athanasakis, Ioannis Petrakis & John Kyriopoulos. (2013) Investigating the Value of Abatacept in the Treatment of Rheumatoid Arthritis: A Systematic Review of Cost-Effectiveness Studies. ISRN Rheumatology 2013, pages 1-15.
Crossref
Crossref
Nicole W. Tsao, Nick J. Bansback, Kam Shojania & Carlo A. Marra. (2012) The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology 26:5, pages 659-676.
Crossref
Crossref
Michael G. Fox, Tausha Stephens, Wael N. Jarjour, Mark W. Anderson & Donald L. Kimpel. (2012) Contrast-Enhanced Magnetic Resonance Imaging Positively Impacts the Management of Some Patients With Rheumatoid Arthritis or Suspected RA. JCR: Journal of Clinical Rheumatology 18:1, pages 15-22.
Crossref
Crossref
Jeffrey R. Curtis & Jasvinder A. Singh. (2011) Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. Clinical Therapeutics 33:6, pages 679-707.
Crossref
Crossref